Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-25
2011-12-13
Bunner, Bridget E (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S325000, C435S375000, C514S018900, C514S885000, C530S350000, C536S023500
Reexamination Certificate
active
08076096
ABSTRACT:
Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6042826 (2000-03-01), Caligiuri et al.
patent: 6046310 (2000-04-01), Queen et al.
patent: 6060054 (2000-05-01), Staerz
patent: 6071716 (2000-06-01), Freeman et al.
patent: 6130316 (2000-10-01), Freeman et al.
patent: 6149905 (2000-11-01), Ostrand-Rosenberg et al.
patent: 6218510 (2001-04-01), Sharpe et al.
patent: 6294660 (2001-09-01), Sharpe et al.
patent: 6319709 (2001-11-01), Ostrand-Rosenberg et al.
patent: 6608180 (2003-08-01), Sharpe et al.
patent: 6653444 (2003-11-01), Freeman et al.
patent: 7238360 (2007-07-01), Shirwan
patent: 2003/0095977 (2003-05-01), Goshorn et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2007/0172504 (2007-07-01), Shirwan et al.
patent: 2007/0172947 (2007-07-01), Shirwan
patent: 2007/0184473 (2007-08-01), Shirwan et al.
patent: WO 97/18307 (1997-05-01), None
patent: WO 97/33617 (1997-09-01), None
patent: WO 99/17801 (1999-04-01), None
patent: WO 01-52664 (2001-07-01), None
Chen et al., “Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fusion Protein Transfer Method,”The Journal of Immunology, 164:705-711 (2000).
Nagata and Suda, “Fas and Fas Ligand: Ipr and gld Mutations,” Immunology Today, 16(1):39-43 (1995).
Le et al., 1994, Enzyme Microb. Technol. 16: 496-500.
Green et al., 1990, Methods in Enzymology, 184: 51-67.
Darling, D., et al., “In Vitro Immune Modulation by Antibodies Coupled to Tumour Cells,”Gene Therapy, 4, (1997), 1350-1360.
Sano, Takeshi, et al., “A Streptavidin-metallothionein Chimera that Allows Specific Labeling of Bioloical Materials with many different heavy meatal ions,”Proc. Nat'l Acad. Sci. USA, vol. 89, Mar. 1992), 1534-1538.
Sano T., et al., 1995, Recombinant Core Streptavidins, Journ. of Biol. Chem., 270(47): 28204-28209.
Pettit et al., 1998, Trends Biotechnol, 16: 343-349.
Pierce Instructions for EZ-Link Sulfo-NHS-LC-Biotin Instructions, 1998, 4 pgs.
Phillips, J. Pharm. Pharmacology 53: 1169-1174, 2001.
Berzofsky JA, et al., “Progress on New Vaccine Strategies for the Immunotherapy and Prevention of Cancer,” Journ. of Clinical Investigation, 113(11): 1515-1525, 2004.
Singh et al., A Novel Approach to Cancer Immunotherapy: Tumor Cells Decorated with CD80 Generate Effective Antitumor Immunity, Cancer Research 63, pp. 4067-4073, 2002.
Yolcu et al., “Cell Membrane Modification for Rapid Display of Proteins as a Novel Means of Immunomodulation: FASL-decorated Cells Prevent Islet Graft Rejection,” Immunity, 17: 795-808, 2002.
Brunschwig et al., Glycosylphosphatidylinositol-Modified Murine B7-1 and B7-2 retain Costimulator Function, Journ. of Immunology, 155: 5498-5505, 1995.
Askenasy et al., 2003, Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection,Circulation, 107: r41-r47.
Sigma No. B2463 Production Information, 1996, 2 pgs.
Airenne et al., “Rapid purification of recombinant proteins fused to chicken avidin,”Gene, vol. 167, pp. 63-68 (1995).
Dubel et al., “Bifunctional and multimetric complexes of streptaavidin fused to single chain antibodies (scFv)”,Journal of Immunological Methods, vol. 178, pp. 201-209 (1995).
Pahler et al., “Characterizaion and Crystallization of Core Streptavidin,”The Journal of Biological Chemistry, vol. 262, No. 29, pp. 13933-13937 (1987).
Daniels et al., “Selective labeling of Neurotransmitter Transporters at the Cell Surface,”Methods in Enzymology, vol. 296, pp. 307-318 (1998).
Hofman et al., “Iminobiotin affinity columns and their application to retrieval of streptavidin,”Pro. Natl. Acad. Sci. USA, vol. 77, No. 8, pp. 4666-4668 (Aug. 1980).
Office Action issued on Jun. 23, 2009 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Office Action issued on Dec. 5, 2008 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Office Action issued on Feb. 26, 2008 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Office Action issued on May 15, 2006 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Office Action issued on Sep. 14, 2005 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Office Action issued on Dec. 2, 2005 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Notice of Allowance issued on Feb. 21, 2007 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Office Action issued Nov. 15, 2006 on Nov. 15, 2006 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Office Action issued Feb. 27, 2006 on Nov. 15, 2006 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Office Action issued Jun. 3, 2005 on Nov. 15, 2006 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Office Action issued Nov. 4, 2004 on Nov. 15, 2006 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Office Action issued Aug. 17, 2004 on Nov. 15, 2006 by the Examiner in U.S. Appl. No. 10/312,245 (US 7,238,360).
Notice of Allowance issued on Apr. 29, 2010 by the Examiner in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Pearl-Yafe et al., “Fas Ligand Enhances Hematopoietic Cell Engraftment Through Abrogation of Alloimmune Responses and Nonimmunogenic Interactions,”Stem Cells, vol. 25, pp. 1448-1455, 2007.
Youlcu et al., “Induction of Tolerance to Cardiac Allografts Using Donor Splenocytes Engineered to Display on Their Surface an Exogenous Fas Ligand Protein,”The Journal of Immunology, vol. 181, pp. 931-939, 2008.
Shirwan , “Bone marrow cells engineered with SA-FasL protein establish durable multilineage mixed allogeneic chimerism,” Unpublished results, discussed in the interview of Apr. 12, 2010 in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Yolcu et al., “Engineering pancreatic islets with a novel form of FasL protein as a robust means of achieving transplantation tolerance,” Unpublished results, discussed in the interview of Apr. 12, 2010 in U.S. Appl. No. 10/202,613 (US 2004/0018170).
Bunner Bridget E
Foley & Lardner LLP
Howard Zachary
University of Louisville Research Foundation Inc.
LandOfFree
Alteration of cell membrane with FasL does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of cell membrane with FasL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of cell membrane with FasL will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314422